Volume 8, Issue 4

Clinical Approaches to MDR Lung Infections

In this issue:

Multidrug resistant lung infections present an increasingly common and increasingly dangerous threat to all individuals with cystic fibrosis.  Common CF pathogens — Pseudomonas aeruginosa, Burkholderia cepacia complex, Achromobacter xylosoxidans, Stenotrophomonas maltophilia — are all showing increasing resistance to clinicians’ usual antibiotic armamentarium.

In this issue, Dr. Claire Elson, from the University of Missouri Kansas City School of Pharmacy, and Dr. Christopher Oermann, from the UMKC School of Medicine, describe strategies for the clinical management of these resistant infections.

Learning objectives:

  • Describe the prevalence of resistant infections in people with CF and the clinical consequences of these infections.
  • Identify the potential treatment strategies for the management of resistant infections in people with CF.



E. Claire Elson, PharmD, BCPPS
E. Claire Elson, PharmD, BCPPS

Clinical Pharmacy Specialist, Pulmonary Medicine/Cystic Fibrosis
Children’s Mercy Kansas City
UMKC School of Pharmacy
Adjunct Professor, University of Missouri-Kansas City School of Pharmacy
Kansas City, MO


Christopher Oermann, MD
Christopher Oermann, MD

Division Director, Division of Pulmonary and Sleep Medicine
Center Director, Cystic Fibrosis Care Center
Children's Mercy Kansas City
Kansas City, MO

Program Directors:

Peter J. Mogayzel, Jr., MD, PhD

Professor of Pediatrics
Director, Cystic Fibrosis Center
Johns Hopkins University School of Medicine
Baltimore, MD

Noah Lechtzin, MD, MHA

Director, Adult Cystic Fibrosis Program
Associate Professor of Medicine
Johns Hopkins University School of Medicine
Baltimore, MD

Suzanne Sullivan, RN, BSN

Senior Clinical Nurse
The Johns Hopkins University
Baltimore, MD

Length of activity:

0.5 hour Physicians
0.5 contact hour Nurses

Launch date: January 18, 2019
Expiration date: January 17, 2021